Related Experiment Video
Updated: Jul 19, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Aldosterone blockade in post-acute myocardial infarction heart failure
Bertram Pitt1, Roberto Ferrari, Mihai Gheorghiade
1University of Michigan Medical Center, William Beaumont Hospital, Cardiovascular Department, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. bpitt@med.umich.edu
Abstract:
Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure V: Medical Management